The 56 references in paper E. Kropacheva S., O. Zemlyanskaya A., A. Dobrovolsky В., Е. Panchenko P., Е. Кропачева С., О. Землянская А., А. Добровольский Б., Е. Панченко П. (2018) “КЛИНИЧЕСКИЕ ФАКТОРЫ И УРОВЕНЬ АНТИКОАГУЛЯЦИИ, ОПРЕДЕЛЯЮЩИЕ РАЗВИТИЕ БЫСТРОЙ ПОТЕРИ ПОЧЕЧНОЙ ФУНКЦИИ У ПАЦИЕНТОВ, ДЛИТЕЛЬНО ПРИНИМАЮЩИХ ВАРФАРИН (5-ЛЕТНЕЕ ПРОСПЕКТИВНОЕ НАБЛЮДЕНИЕ) // CLINICAL FACTORS AND ANTICOAGULATION LEVEL THAT DETERMINE THE SUDDEN LOSS OF KIDNEY FUNCTION IN PATIENTS LONG-TAKING WARFARIN (A 5-YEAR PROSPECTIVE, OBSERVATIONAL STUDY)” / spz:neicon:aterotromboz:y:2018:i:1:p:107-121

1
Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. Приложение 2, 2011, 10 (6). / National guidelines for cardiovascular prevention. Kardiovaskulyarnaya Terapiya i Profilaktika. Annex 2, 2011, 10 (6).
(check this in PDF content)
2
Soliman EZ, Prineas RJ, Go AS et al. Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC). Am Heart J, 2010, 159: 1102–1127.
(check this in PDF content)
3
Klein R, Klein BE, Moss SE. The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care, 1999, 22 (5): 743–751.
(check this in PDF content)
4
ESH / ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 2013, 34: 2159–2219.
(check this in PDF content)
5
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J, 2012, 33: 1635–7011.
(check this in PDF content)
6
Stevens PE, Levin A. Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline. Annals of Internal Medicine, 2013, 158 (11): 825–830. pmid: 23732715.
(check this in PDF content)
7
Beker BM, Corleto MG, Fieiras C, Musso CG. Novel acute kidney injury biomarkers: their characteristics, utility and concerns. Int Urol Nephrol, 2018 Jan 6. doi: 10.1007 / s11255-017–1781-x.
(check this in PDF content)
8
Rysz J, Gluba-Brzózka A, Franczyk B et al. Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome. Int J Mol Sci, 2017 Aug 4, 18 (8). pii: E1702. doi: 10.3390 / ijms18081702.
(check this in PDF content)
9
Bhavsar NA, Koettgen A, Coresh J, Astor BC. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM-1) as Predictors of Incident CKD Stage 3: The Atherosclerosis Risk in Communities (ARIC) Study. American Journal of Kidney Diseases, 2012, 60 (2): 233–240.
(check this in PDF content)
10
O’Seaghdha CM, Hwang S-J, Larson MG et al. Analysis of a Urinary Biomarker Panel for Incident Kidney Disease and Clinical Outcomes. Journal of the American Society of Nephrology, 2013, 24 (11): 1880– 1888.
(check this in PDF content)
11
Nejat M, Pickering JW, Walker RJ, Endre ZH. Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit. Nephrol Dial Transplant, 2010, 25: 3283–3289.
(check this in PDF content)
12
Steubl D, Block M, Herbst V et al. Plasma Uromodulin Correlates With Kidney Function and Identifies Early Stages in Chronic Kidney Disease Patients. Medicine (Baltimore), 2016 Mar, 95 (10): e3011. doi: 10.1097 / MD.0000000000003011.
(check this in PDF content)
13
Prajczer S, Heidenreich U, Pfaller W et al. Evidence for a role of uromodulin in chronic kidney disease progression. Nephrol Dial Transplant, 2010 Jun, 25 (6): 1896–1903. doi: 10.1093 / ndt / gfp748.
(check this in PDF content)
14
Lobato GR, Lobato MR, Thomé FS, Veronese FV. Performance of urinary kidney injury molecule-1, neutrophil gelatinase-associated lipocalin, and N-acetylβ-D-glucosaminidase to predict chronic kidney disease progression and adverse outcomes. Braz J Med Biol Res, 2017 Mar 30, 50 (5): e6106.
(check this in PDF content)
15
Obermüller N, Geiger H, Weipert C, Urbschat A. Current developments in early diagnosis of acute kidney injury. Int Urol Nephrol, 2014 Jan, 46 (1): 1–7. doi: 10.1007 / s11255-013-0448–5.
(check this in PDF content)
16
Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC). Am Heart J, 2010, 159: 1102–1107.
(check this in PDF content)
17
Fanola CL, Mooney D, Cowan AJ et al. Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants. Am Heart J, 2017, 184: 150–155.
(check this in PDF content)
18
Böhm M, Ezekowitz MD, Connolly Stuart J et al. Changes in Renal Function in Patients With Atrial Fibrillation. JACC, 2015, 65: 2481–2493.
(check this in PDF content)
19
Brodsky SV, Nadasdy T, Rovin B H et al. Warfarinrelated nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney International, 2011, 80: 181–189.
(check this in PDF content)
20
Brodsky SV, Hebert LA. Anticoagulant-Related Nephropathy: Is an AKI Elephant Hiding in Plain View? J Am Coll Cardiol, 2016, 68 (21): 2284–2286.
(check this in PDF content)
21
Chatrou ML, Winckers K, Hackeng TM et al. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev, 2012 Jul, 26 (4): 155–166.
(check this in PDF content)
22
Кропачева Е. С., Землянская О. А., Добровольский А. Б., Панченко Е. П. Эффективность длительной терапии варфарином: влияние на частоту ишемических нарушений мозгового кровообращения ПРАКТИЧЕСКИЕ ВОПРОСЫ ПРИМЕНЕНИЯ АНТИКОАГУЛЯНТОВ и клинические предикторы их развития (результаты проспективного 10-летнего наблюдения). Атеротромбоз, 2017, 2: 115–130. / Kropacheva ES, Zemlyanskaya OA, Dobrovolsky AB, Panchenko EP. The effectiveness of long-term warfarin therapy: impact on the frequency of ischemic disorders of cerebral circulation and the clinical predictors of their development (the results of a prospective 10-year observation). Aterotromboz, 2017, 2: 115–130.
(check this in PDF content)
23
Кропачева Е. С., Землянская О. А., Добровольский А. Б., Панченко Е. П. Эффективность длительной терапии варфарином: влияние на частоту ишемических нарушений мозгового кровообращения и клинические предикторы их развития (результаты проспективного 10-летнего наблюдения). Атеротромбоз, 2017, 1: 145– 162. / Kropacheva ES, Zemlyanskaya OA, Dobrovolsky AB, Panchenko EP. The effectiveness of long-term warfarin therapy: impact on the frequency of ischemic disorders of cerebral circulation and the clinical predictors of their development (the results of a prospective 10-year observation). Aterotromboz, 2017, 2: 115–130.
(check this in PDF content)
24
Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med, 2004, 351: 1296–1305.
(check this in PDF content)
25
Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med, 2012, 367: 625–635.
(check this in PDF content)
26
Bautista J, Bella A, Chaudhari A. Advanced chronic kidney disease in non-valvular atrial fibrillation: extending the utility of R2CHADS2 to patients with advanced renal failure. Clin Kidney J, 2015 Apr, 8 (2): 226–231.
(check this in PDF content)
27
Землянская О. А., Кропачева Е. С., Добровольский А. Б., Панченко Е. П. Функция почек у больных, длительно принимающих варфарин (5-летнее проспективное наблюдение). Тер Архив, 2017, 89 (9): 78–86. / Zemlyanskaya OA, Kropacheva ES, Dobrovolsky AB, Panchenko EP. Kidney function in patients long-taking warfarin (5-year prospective observation). Ter Arkhiv, 2017, 89 (9): 78–86.
(check this in PDF content)
28
Damman K, Navis G, Voors AA et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail, 2007 Oct, 13 (8): 599–608.
(check this in PDF content)
29
Dries DL, Exner DV, Domanski MJ et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol, 2000 Mar 1, 35 (3): 681–689.
(check this in PDF content)
30
Damman K, Valente MA Voors AA et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated metaanalysis. Eur Heart J, 2014 Feb, 35 (7): 455–469. doi: 10.1093 / eurheartj / eht386. Epub 2013 Oct 27.
(check this in PDF content)
31
Kakkar AK, Mueller I, Bassand JP et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). AHJ, 2012, 163 (1): 13–19.
(check this in PDF content)
32
Haroun MK, Jaar BG, Hoffman SC et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol, 2003 Nov, 14 (11): 2934–2941.
(check this in PDF content)
33
Eriksenand BO, Ingebretsen OC. The progression of chronic kidney disease: A 10-yearpopulation-based study of the effects of gender and age. Kidney Int, 2006 Jan, 69 (2): 375–382.
(check this in PDF content)
34
Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of non diabeticrenal disease: a meta-analysis. J Am SocNephrol, 2000 Feb, 11 (2): 319–329.
(check this in PDF content)
35
Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey. Am J Kidney Dis, 2003 Jan, 41 (1): 1–12.
(check this in PDF content)
36
Luo Y, Li X, Li J et al. Peripheral arterial disease, chronic kidney disease, and mortality: the Chinese Ankle Brachial Index Cohort Study. Vasc Med, 2010 Apr, 15 (2): 107–112. doi: 10.1177 / 1358863X09357230. Epub 2010 Feb 4.
(check this in PDF content)
37
Paraskevas KI, Giannoukas AD, Mikhailidis DP. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected. Ann Vasc Surg, 2009 Sep-Oct, 23 (5): 690–699. doi: 0.1016 / j.avsg.2009.06.002.
(check this in PDF content)
38
Fanola CL, Mooney D, Cowan AJ et al. Incidence of severe renal dysfunction among individuals taking warfarin and implications for non – vitamin K oral anticoagulants. Am Heart J, 2017 Feb, 184: 150–155. doi: 10.1016 / j.ahj.2016.08.017. Epub 2016 Nov 4.
(check this in PDF content)
39
Beddhu S, Rocco MV, Toto R et al., SPRINT Research Group. Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease: A Secondary Analysis of a Randomized Trial. Ann Intern Med, 2017 Sep 19, 167 (6): 375–383. doi: 10.7326 / M16–2966. Epub 2017 Sep 5.
(check this in PDF content)
40
MacIsaac RJ, Jerums G, Ekinci EI. Effects of glycaemic management on diabetic kidney disease. World J Diabetes, 2017 May 15, 8 (5): 172–186. Published online 2017 May 15. doi: 10.4239 / wjd.v8.i5.172 PMCID: PMC5437616.
(check this in PDF content)
41
Bash LD, Selvin E, Steffes M et al. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy: Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med, 2008, 168: 2440–2447. PMC free article. PubMed.
(check this in PDF content)
42
Shurraw S, Hemmelgarn B, Lin M et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med, 2011, 171: 1920–1927. PubMed.
(check this in PDF content)
43
Levey AS, Coresh J. Chronic kidney Risk Models to Predict Chronic Kidney Disease and Its Progression: A Systematic Review. Lancet, 2012, 379: 165–180. Published OnlineAugust 15, 2011. doi: 10.1016 / S0140– 6736 (11) 60178–5.
(check this in PDF content)
44
Zeeuw D. Albuminuria, not only a cardiovascular / renal risk markerbut also a target for treatment? Kidney Int, 2004, 66: S2–6.
(check this in PDF content)
45
Levey AS, Cattran D, Friedman A et al. Proteinuria as a surrogate outcome in CKD: report of a scientifi c workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis, 2009, 54: 205–226.
(check this in PDF content)
46
Dreyer G, Hull S, Mathur R et al. Progression of chronic kidney disease in a multi-ethnic community cohort of patients with diabetes mellitus. Diabet Med, 2013 Aug, 30 (8): 956–963. doi: 10.1111 / d m e . 12197. Epub 2013 Apr 20.
(check this in PDF content)
47
Fihn SD, McDommel M, Matin D et al. Risk factors fоr complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Followup Study Groop. Ann Intern Med, 1993 Apr1, 118 (7): 511–520.
(check this in PDF content)
48
Mhairi Copland, Walker ID, Campbell R. Oral Anticoagulation and Hemorrhagic Complications in an Elderly Population With Atrial Fibrillation. Arch Inter Med, 2001, 161, 61 (17): 2125–2128.
(check this in PDF content)
49
Palareti G, Leali N, Coccheri S et al. Hemorrhagic complications of oral anticoagulant therapy: results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy). G Ital Cardiol, 1997, 27 (3): 231–243.
(check this in PDF content)
50
Gorter JW. Major bleeding during anticoagulation after cerebral ishemia: patterns asnd risk factors. Stroke Prevention in Reversible Ishemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology, 1999, 53 (6): 1319–1327.
(check this in PDF content)
51
Gullov AL, Koefoed BG, Petersen P. Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med, 1999, 159 (12): 1322–1328.
(check this in PDF content)
52
Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med, 1995, 333 (1): 5–10.
(check this in PDF content)
53
Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet, 1996, 348: 423–428.
(check this in PDF content)
54
Fitzmaurice DA, Accetta G, Haas S et al. GARFIELD-AF Investigators Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists. Br J Haematol, 2016 Aug, 174 (4): 610–623.
(check this in PDF content)
55
Diener HC. Executive Steering Committee of the SPORTIFF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis, 2006, 21 (4): 279–293.
(check this in PDF content)
56
Sharma SG, Bomback AS, Radhakrishnan J et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol, 2013, 8 (10): 1718–1724.
(check this in PDF content)